Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Open access

Published version of a preprint

Abstract

Predictive models of immune protection from COVID-19 are urgently needed to identify correlates of protection to assist in the future deployment of vaccines. To address this, we analyzed the relationship between in vitro neutralization levels and the observed protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using data from seven current vaccines and from convalescent cohorts. We estimated the neutralization level for 50% protection against detectable SARS-CoV-2 infection to be 20.2% of the mean convalescent level (95% confidence interval (CI) = 14.4-28.4%). The estimated neutralization level required for 50% protection from severe infection was significantly lower (3% of the mean convalescent level; 95% CI = 0.7-13%, P = 0.0004). Modeling of the decay of the neutralization titer over the first 250 d after immunization predicts that a significant loss in protection from SARS-CoV-2 infection will occur, although protection from severe disease should be largely retained. Neutralization titers against some SARS-CoV-2 variants of concern are reduced compared with the vaccine strain, and our model predicts the relationship between neutralization and efficacy against viral variants. Here, we show that neutralization level is highly predictive of immune protection, and provide an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01377-8

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

23 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 4

  1. Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19 (Regeneron press release, 26 January 2021). https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-reports-positive-interim-data-regen-covtm-antibody (2021).
  2. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020). · doi:10.1056/nejmoa2027906 · Paper page
  3. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial (Novavax press release 28 January 2021) https://ir.novavax.com/ (2021).
  4. Bharat Biotech Announces Phase 3 Results of COVAXIN®: India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81% (Bharatbiotech press release 3 March 2021) https://www.bharatbiotech.com/press_releases.html (2021).

Cited by

See all 3,742

Metadata

Authors
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P.
Affiliations
  • UNSW Sydney (AU)
  • The University of Sydney (AU)
  • The University of Melbourne (AU)
  • Australian Research Council (AU)
Corresponding author
  • Triccas, James A.
  • Davenport, Miles P.
Venue
Nature Medicine
Published
2021-05-17
Volume
27
Issue
7
Pages
1205-1211
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3163785571
Cited by
3,742
References
60
Citations by year
2026: 171 · 2025: 304 · 2024: 431 · 2023: 776 · 2022: 1433 · 2021: 621
FWCI
259.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • medRxiv (acceptedVersion)
  • PubMed (publishedVersion)
  • The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by)
Funders
  • Department of Health | National Health and Medical Research Council (GNT1173027, GNT1173528, GNT1123673, GNT2002073, GNT1149990, GNT1153493)
  • Department of Health, Australian Government (MRF2005544)
  • State Government of Victoria
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
SARS-CoV-2, COVID-19 vaccines, neutralizing antibodies, immunoprotection, correlates of protection, neutralization titers, convalescent sera, vaccine efficacy, waning immunity, variants of concern
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Viral, Humans, Severity of Illness Index, Logistic Models, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1038/s41591-021-01377-8
The paper
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. https://doi.org/10.1038/s41591-021-01377-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.